1. Home
  2. LGND vs TMDX Comparison

LGND vs TMDX Comparison

Compare LGND & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • TMDX
  • Stock Information
  • Founded
  • LGND 1987
  • TMDX 1998
  • Country
  • LGND United States
  • TMDX United States
  • Employees
  • LGND N/A
  • TMDX N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • LGND Health Care
  • TMDX Health Care
  • Exchange
  • LGND Nasdaq
  • TMDX Nasdaq
  • Market Cap
  • LGND 2.2B
  • TMDX 2.4B
  • IPO Year
  • LGND 1992
  • TMDX 2019
  • Fundamental
  • Price
  • LGND $120.67
  • TMDX $71.95
  • Analyst Decision
  • LGND Strong Buy
  • TMDX Buy
  • Analyst Count
  • LGND 6
  • TMDX 11
  • Target Price
  • LGND $145.00
  • TMDX $116.10
  • AVG Volume (30 Days)
  • LGND 79.6K
  • TMDX 1.3M
  • Earning Date
  • LGND 02-27-2025
  • TMDX 02-27-2025
  • Dividend Yield
  • LGND N/A
  • TMDX N/A
  • EPS Growth
  • LGND 160.46
  • TMDX N/A
  • EPS
  • LGND 2.47
  • TMDX 0.94
  • Revenue
  • LGND $152,422,000.00
  • TMDX $401,090,000.00
  • Revenue This Year
  • LGND $26.86
  • TMDX $81.61
  • Revenue Next Year
  • LGND $14.95
  • TMDX $22.52
  • P/E Ratio
  • LGND $48.82
  • TMDX $76.78
  • Revenue Growth
  • LGND N/A
  • TMDX 109.09
  • 52 Week Low
  • LGND $67.72
  • TMDX $55.00
  • 52 Week High
  • LGND $129.90
  • TMDX $177.37
  • Technical
  • Relative Strength Index (RSI)
  • LGND 59.36
  • TMDX 52.52
  • Support Level
  • LGND $110.42
  • TMDX $66.81
  • Resistance Level
  • LGND $119.26
  • TMDX $80.00
  • Average True Range (ATR)
  • LGND 3.82
  • TMDX 4.14
  • MACD
  • LGND 0.61
  • TMDX 0.57
  • Stochastic Oscillator
  • LGND 81.35
  • TMDX 48.74

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: